EUVIMEDEUVIMED entdecken
Crossref

Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism

Antonella Tufano iD, Alberto Corsini, Anna Guida, Silvia Costabile, Nicola Ferri, Mario Mandalà

Seminars in Thrombosis and Hemostasis · 12.05.2026

DOI: 10.1055/a-2860-6033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 12.05.2026. Verfasst von Antonella Tufano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractCancer-associated thrombosis (CAT) remains a major cause of morbidity and mortality in patients with malignancy. Direct oral anticoagulants (DOACs) have expanded the therapeutic armamentarium for CAT and are now widely used as alternatives to low molecular weight heparins (LMWHs). However, the increasing complexity of contemporary oncologic care has heightened concerns regarding clinically relevant drug–drug interactions (DDIs). All DOACs are substrates of P-glycoprotein, and some undergo partial metabolism via cytochrome P4503A4, rendering them more susceptible to pharmacokinetic (PK) modulation by anticancer agents. Moreover, several antineoplastic drugs exert intrinsic prothrombotic or hemorrhagic effects, thereby introducing pharmacodynamic interactions that may further destabilize the already dysregulated hemostatic system in cancer. Despite these theoretical concerns, evidence from randomized trials and real-world studies remains limited and largely derived from subgroup analyses, PK investigations in healthy volunteers, or retrospective registries. Consequently, the true clinical magnitude of DDIs in CAT remains incompletely defined. This review critically appraises the pharmacological basis, clinical evidence, and translational implications of DDIs between DOACs and anticancer therapies. We propose that DDIs in CAT should not be viewed solely as PK phenomena, but also as potential biological amplifiers of cancer-associated coagulopathy. Until prospective, dedicated studies become available, a structured/individualized approach—integrating thrombotic/bleeding risk, interacting medications, and patient-specific factors—is warranted.

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti," University of Milan, Milan, Lombardy, Italy.
  • Centro per le Malattie Emorragiche Congenite e Malattie Trombotiche, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Campania, Italy.
  • Unit of Medical Oncology, University of Perugia, Perugia, Umbria, Italy.
  • Department of Medicine, University of Padova, Padua, Veneto, Italy.

ORCID-Profile: Antonella Tufano

Zitieren

APA

Tufano, A., Corsini, A., Guida, A., Costabile, S., Ferri, N., & Mandalà, M. (2026). Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/a-2860-6033

Vancouver

Tufano A, Corsini A, Guida A, Costabile S, Ferri N, Mandalà M. Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism. Seminars in Thrombosis and Hemostasis. 2026. doi:10.1055/a-2860-6033

BibTeX
@article{Tufano2026,
  author = {Tufano, Antonella and Corsini, Alberto and Guida, Anna and Costabile, Silvia and Ferri, Nicola and Mandalà, Mario},
  title = {Hemostatic Aspects of Interactions Between Anticancer Drugs and Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2026},
  doi = {10.1055/a-2860-6033}
}
Kostenlos starten →